Article
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Chinese clinical oncology - 1 Mar 2015
Friedberg Jonathan W
Abstract excerpt
Although diffuse large B-cell lymphoma (DLBCL) is curable with standard chemoimmunotherapy, over 30% of patients with advanced stage disease experience refractory disease or progression. Recent studies suggest that rearrangement of the myc oncogene occurs in approximately 10% of patients with DLBCL, and confers a very poor prognosis, particularly when there is concomitant rearrangement of bcl-2, a condition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
